[go: up one dir, main page]

PT2310044T - Imunoterapia antitumor - Google Patents

Imunoterapia antitumor

Info

Publication number
PT2310044T
PT2310044T PT97767461T PT09776746T PT2310044T PT 2310044 T PT2310044 T PT 2310044T PT 97767461 T PT97767461 T PT 97767461T PT 09776746 T PT09776746 T PT 09776746T PT 2310044 T PT2310044 T PT 2310044T
Authority
PT
Portugal
Prior art keywords
tumor immunotherapy
immunotherapy
tumor
Prior art date
Application number
PT97767461T
Other languages
English (en)
Inventor
Filaci Gilberto
Indiveri Francesco
Traverso Paolo
Original Assignee
Mediolanum Farm S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farm S P A filed Critical Mediolanum Farm S P A
Publication of PT2310044T publication Critical patent/PT2310044T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT97767461T 2008-06-16 2009-06-16 Imunoterapia antitumor PT2310044T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6177808P 2008-06-16 2008-06-16

Publications (1)

Publication Number Publication Date
PT2310044T true PT2310044T (pt) 2016-11-18

Family

ID=41507473

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97767461T PT2310044T (pt) 2008-06-16 2009-06-16 Imunoterapia antitumor

Country Status (14)

Country Link
US (1) US8828403B2 (pt)
EP (1) EP2310044B1 (pt)
JP (1) JP5787752B2 (pt)
CA (1) CA2727388C (pt)
CY (1) CY1118215T1 (pt)
DK (1) DK2310044T3 (pt)
ES (1) ES2602453T3 (pt)
HR (1) HRP20161434T1 (pt)
HU (1) HUE030984T2 (pt)
LT (1) LT2310044T (pt)
PL (1) PL2310044T3 (pt)
PT (1) PT2310044T (pt)
SI (1) SI2310044T1 (pt)
WO (1) WO2010003520A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2536830T (lt) 2010-02-16 2019-11-11 Ultimovacs Asa Polipeptidai
CN104661672B (zh) 2012-05-11 2017-03-08 珍白斯凯尔有限公司 用于预防或治疗败血症的组合物
KR20210025132A (ko) 2012-05-11 2021-03-08 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP2899200B1 (en) * 2012-09-19 2020-05-06 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP2899199B1 (en) * 2012-09-19 2019-07-03 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102093093B1 (ko) * 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
JP6474786B2 (ja) * 2013-04-19 2019-02-27 ジェムバックス アンド カエル カンパニー，リミティド 虚血性損傷の治療及び予防用の組成物
AU2014275610B2 (en) 2013-06-07 2018-06-14 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
TWI539960B (zh) * 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
JP6382972B2 (ja) * 2013-10-23 2018-08-29 ジェムバックス アンド カエル カンパニー，リミティド 前立腺肥大治療用及びその予防用の組成物
KR102307567B1 (ko) * 2013-11-12 2021-10-01 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
CN105939723B (zh) * 2013-12-17 2020-02-28 珍白斯凯尔有限公司 前列腺癌治疗用组合物
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
EP3138399B1 (en) 2014-04-30 2023-09-06 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
WO2023048530A1 (ko) * 2021-09-24 2023-03-30 주식회사 차백신연구소 종양 연관 항원으로부터 유래된 펩타이드 및 리포펩타이드와 면역활성물질로 구성되는 아쥬번트를 포함하는 항암 백신 조성물 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0105238D0 (en) 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
AU2002363231A1 (en) 2001-10-29 2003-05-12 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
ITMI20032121A1 (it) * 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi

Also Published As

Publication number Publication date
ES2602453T3 (es) 2017-02-21
US8828403B2 (en) 2014-09-09
JP5787752B2 (ja) 2015-09-30
SI2310044T1 (sl) 2017-03-31
JP2011524390A (ja) 2011-09-01
HRP20161434T1 (hr) 2017-02-24
EP2310044B1 (en) 2016-08-24
EP2310044A2 (en) 2011-04-20
DK2310044T3 (en) 2016-12-12
CA2727388C (en) 2017-08-29
US20110135692A1 (en) 2011-06-09
WO2010003520A2 (en) 2010-01-14
WO2010003520A3 (en) 2010-07-15
CA2727388A1 (en) 2010-01-14
LT2310044T (lt) 2016-12-27
HUE030984T2 (en) 2017-06-28
PL2310044T3 (pl) 2017-04-28
CY1118215T1 (el) 2017-06-28

Similar Documents

Publication Publication Date Title
SI2310044T1 (sl) Proti-tumorska imunoterapija
WO2010080124A9 (en) Nkg2d-fc for immunotherapy
IL210818A0 (en) Gemstone viewer
GB0815216D0 (en) Interleukin
EP2323928A4 (en) CARRIER ASSEMBLY
IL208990A0 (en) Novel phenylimidazopyrazines
EP2056861A4 (en) IMPF-IMMUNOTHERAPY
GB0907413D0 (en) Novel methods
GB2451357B (en) Ceramic Armour
GB0811360D0 (en) Methods
ZA200904941B (en) Novel methods
GB2471221B (en) Methods
GB0818650D0 (en) Methods
IL207958A0 (en) Allogeneic cancer cell - based immunotherapy
GB0810012D0 (en) Fixture means
GB0817482D0 (en) No-catch zip
GB0806577D0 (en) Fastening means
GB0812589D0 (en) Adoptive immunotherapy
GB0712715D0 (en) Adoptive immunotherapy
GB0711729D0 (en) Adoptive immunotherapy
AU2008903232A0 (en) Cancer immunotherapy
AU2009903449A0 (en) Cancer Immunotherapy
PH32008000431S1 (en) Gemstone
PH32008000422S1 (en) Gemstone
GB0811114D0 (en) Mud-monster + tail-safe